04 September 2010
Keywords: AstraZeneca, Brilinta, AHA, Research, FDA filing
Article | 19 November 2009
Anglo-Swedish drug major AstraZeneca announced the results of the Phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (trade name Brilinta) at the annual American Heart Association Scientific Sessions in Orlando, Florida, with the first study’s results being simultaneously published in the medical journal Circulation. The company has also filed for approval of the drug in the USA.
T Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.